PEGylated Molybdenum-Iodine Nanocluster as a Promising Radiodynamic Agent against Prostatic Adenocarcinoma

0585208 - ÚMG 2025 RIV US eng J - Journal Article
Přibyl, T. - Rumlová, M. - Mikyšková, Romana - Reiniš, Milan - Kaňa, A. - Škoch, Karel - Zelenka, J. - Kirakci, Kaplan - Ruml, T. - Lang, Kamil
PEGylated Molybdenum-Iodine Nanocluster as a Promising Radiodynamic Agent against Prostatic Adenocarcinoma.
Inorganic Chemistry. Roč. 63, č. 9 (2024), s. 4419-4428. ISSN 0020-1669. E-ISSN 1520-510X
R&D Projects: GA ČR(CZ) GA21-11688S
Institutional support: RVO:68378050 ; RVO:61388980
Keywords : induced photodynamic therapy * cluster complexes * cancer * nanoparticles * luminescence * (mo6i8)(4+)
OECD category: Cell biology
Impact factor: 4.6, year: 2022
Method of publishing: Limited access
https://pubs.acs.org/doi/10.1021/acs.inorgchem.4c00084

The combination of photodynamic therapy and radiotherapy has given rise to a modality called radiodynamic therapy (RDT), based on reactive oxygen species-producing radiosensitizers. The production of singlet oxygen, O-2((1)Delta(g)), by octahedral molybdenum (Mo-6) clusters upon X-ray irradiation allows for simplification of the architecture of radiosensitizing systems. In this context, we prepared a radiosensitizing system using copper-free click chemistry between a Mo-6 cluster bearing azido ligands and the homo-bifunctional linker bis-dPEG(11)-DBCO. The resulting compound formed nanoparticles, which featured production of O-2((1)Delta(g)) and efficient cellular uptake, leading to remarkable photo- and radiotoxic effects against the prostatic adenocarcinoma TRAMP-C2 cell line. Spheroids of TRAMP-C2 cells were also used for evaluation of toxicity and phototoxicity. In vivo experiments on a mouse model demonstrated that subcutaneous injection of the nanoparticles is a safe administration mode at a dose of up to 0.08 g kg(-1). The reported results confirm the relevancy of Mo-6-based radiosensitizing nanosystems for RDT.
Permanent Link: https://hdl.handle.net/11104/0352951